Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | GCKR | Q14397 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353284 | 1.00 | HSD11B1 (0.51) | HSD11B1PTGDRCHRM2CHRM1CHRM5 | |
| SCHEMBL5776828 | 0.89 | HSD11B1 (0.51) | HSD11B1PTGDRCHRM2CHRM1CHRM5 | |
| SCHEMBL5776832 | 0.89 | HSD11B1 (0.51) | HSD11B1PTGDRCHRM2CHRM1CHRM5 | |
| SCHEMBL5480678 | 0.88 | PPARD (0.52) | HSD11B1CHRM2CHRM1CHRM5CHRM3 | |
| SCHEMBL5776562 | 0.85 | PTGDR (0.48) | HSD11B1PTGDR | |
| SCHEMBL6348338 | 0.84 | HSD11B1 (0.53) | HSD11B1PTGDRCHRM2CHRM1CHRM5 | |
| SCHEMBL6348336 | 0.84 | HSD11B1 (0.53) | HSD11B1PTGDRCHRM2CHRM1CHRM5 | |
| SCHEMBL6349279 | 0.83 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL6349276 | 0.83 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL6353294 | 0.83 | MAPT (0.47) | PTGDRCHRM2GCKR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | HSD11B1 668/4885PTGDR 371/4885CHRM2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.